Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury (Q38194363)

30 August 2017

1 reference

title

Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury (English)

1 reference

30 August 2017

Alyssa H Yoon

1

1 reference

PubMed ID

24607763

30 August 2017

Yumei Ye

series ordinal

2

1 reference

PubMed ID

24607763

30 August 2017

Yochai Birnbaum

series ordinal

3

1 reference

30 August 2017

6 March 2014

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

30 August 2017

1 reference

30 August 2017

19

1 reference

30 August 2017

5

1 reference

30 August 2017

417-425

1 reference

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

30 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Cardiovascular effects of gliptins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Cardiovascular effects of glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Cardioprotective effects of incretin during ischaemia-reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: a translational perspective for the cardiologist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Exenatide exerts a potent antiinflammatory effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

The anti-ischemic and anti-anginal properties of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414524482

21 January 2018

Identifiers

DOI

10.1177/1074248414524482

1 reference

30 August 2017

1 reference

PubMed ID

24607763